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Abstract
Purpose:  Percutaneous  image-guided  cryoablation  has  not  been  validated  for  local  management
of recurrence  of  soft  tissue  sarcoma  (STS)  of  the  trunk  or  limbs.  This  study  aims  to  identify
selection  criteria  for  cryoablation  in  order  to  standardize  indications  of  this  treatment.
Patients  and  methods:  Between  2000  and  2010,  46  patients  (57  tumors)  presenting  local  recur-
rences of  STS  of  the  trunk  or  limbs  and  treated  following  standards  of  care  were  selected  from
our institutional  database.  Eligibility  for  cryoablation  was  assessed  by  two  radiologists  according
to predeﬁned  criteria:  maximal  diameter  size  of  the  tumor  ≤  10  cm,  distance  to  skin  >5  mm,  dis-
tance to  neurovascular  structures  3  mm  at  least,  absence  of  articular  involvement  and  planned
cryoablation  covering  the  entire  lesion  volume.  Characteristics  and  outcomes  were  compared.
Results: There  was  nearly  perfect  agreement  for  all  criteria  (k  coefﬁcient  ranging  from  0.83
to 0.98)  between  both  readers.  A  subgroup  of  13  patients  was  identiﬁed  as  eligible  for  cryoab-
lation. Locations  to  the  trunk,  pelvic  girdle  or  shoulder  were  signiﬁcantly  more  present  in  the
cryoablation  group  (P  =  0.002).  In  this  group,  tumors  were  mainly  located  deeply  (P  =  0.002)
with great  axes  ≤  5  cm  (P  =  0.044).  High  local  tumor  aggressiveness  (P  =  0.016)  and  differenti-
ated myxoid  liposarcoma  or  myxoﬁbrosarcoma  (P  =  0.007)  were  more  frequent  in  the  eligible
group.
Abbreviations: CT, computed tomography; GE, gradient echo; Gd, gadolinium; MR, magnetic resonance; ROI, region of interest.
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Conclusion:  Based  on  these  criteria,  two  groups  of  patients  with  local  relapse  of  STS  can  be
identiﬁed. These  results  may  improve  the  standardization  of  selection  of  patients  who  could
be candidates  for  cryoablation.
© 2014  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
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ocal  management  of  recurrence  of  soft  tissue  sarcoma  (STS)
f  the  trunk  or  limbs  is  still  a  challenge  and  depends  princi-
ally  of  the  prognosis  of  the  disease  [1].  Treatments  depend
f  stages  proposed  by  the  American  Joint  Committee  on  Can-
er  (AJCC)  and  the  International  Union  against  Cancer  (UICC)
n  addition  of  tumour  size  and  depth  or  tumour  resectability.
n  cases  of  good  prognosis  (i.e.  late  or  low-grade  recur-
ence),  a  new  curative  treatment  may  be  proposed,  while  in
ases  of  poor  prognosis  (i.e.  early  or  high-grade  recurrences
r  with  metastases),  a  palliative  option  must  be  considered.
herefore,  according  to  ESMO  Clinical  Practice  Guidelines
2],  surgery  is  still  the  standard-of-care  for  limited  disease
hereas  chemo-  or  radiotherapy  can  be  discussed  in  case  of
xtensive  disease  or  recurrences.
Recently,  percutaneous  image-guided  procedures  such
s  radiofrequency  or  cryoablation  have  been  proposed  in
everal  soft  tissue  tumors  as  alternatives  to  surgery  [3].
hese  techniques  are  discussed  case-by-case  because  they
ffer  less  invasive  alternatives  for  locoregional  treatment
f  primary  or  secondary  tumors,  especially  for  patients
ho  are  poor  surgical  candidates,  irrespective  of  the  rea-
ons.  Due  to  its  minimally  invasive  nature  and  real-time
ontrol  of  ablative  volume  and  margins,  cryoablation  has
een  recently  performed  in  soft  tissues  for  the  treatment
f  benign  tumors  such  as  desmoid  tumors  [4,5]  or  vascular
alformations  [6,7],  and  for  soft  tissue  metastases  [8]. Per-
ormed  under  ultrasound  (US),  computed  tomography  (CT)
r  magnetic  resonance  imaging  (MRI)  guidance,  these  stud-
es  have  reported  low  morbidity,  excellent  tolerance  and
dequate  local  control.
As  the  literature  about  the  indication  and  feasibility  of
ryoablation  in  the  management  of  STS  is  scarce  [9,10], the
urpose  of  this  retrospective  study  was  to  identify  selection
riteria  for  cryoablation  of  local  recurrence  of  STS  of  the
runk  and  the  limbs  in  order  to  standardize  indications  of
his  treatment.
atients and methods
atients
nstitutional  review  board  approval  was  obtained  for  this
etrospective  study.  Medical  records  of  all  patients  diag-
osed  with  a  local  recurrence  of  soft  tissue  sarcoma  of  the
imbs  or  trunk  wall  in  our  institution  between  2000  and  2010
nd  explored  with  MR  or  CT  imaging  were  retrospectively
elected  from  our  prospectively  maintained  institutional
atabase  and  reviewed.  In  addition,  thorough  review  of  all
edical  or  pathological  records,  treatments,  follow-up  and
omplications  were  compiled  for  all  patients.
r
p
s
fThen,  forty-six  patients  (30  male,  16  female)  with  57
umors  were  selected  from  the  institutional  database  and
ncluded  in  this  study  (Fig.  1).  Mean  age  was  64.9  years
range:  23.4—84.2).  Thirty-four  presented  co-morbidities
73.9%)  and  10  were  ASA  3  (21.7%).  Among  all  tumors,
he  pathology  diagnosis  ware  unclassiﬁed/myxoﬁbro  sar-
omas  for  24  (52.2%),  liposarcomas  for  15  (32/6%)  and
ther  for  seven  (15.2%).  Mean  size  was  64  mm  (10—178).
umor  grades  were  2  for  10  tumors  (21.7%)  and  3  for  21
45.7%).  Multiple  tumors  were  observed  in  seven  patients
15.2%)  and  metastatic  disease  was  reported  for  27  patients
58.7%).  Surgery  was  performed  alone  in  16  patients  (34.8%)
r  combined  with  other  therapeutic  modalities  in  24  patients
52.2%),  as  radiotherapy  or  brachytherapy-only  for  11
23.9%),  chemotherapy-only  for  5  (10.9%),  or  both  for
 (8.7%).  Four  patients  had  surgery  associated  with  iso-
ated  limb  perfusion  associated  (n  =  3)  or  not  (n  =  1)  with
ther  therapeutic  option,  such  as  chemotherapy  (n  =  1)
r  radiotherapy  (n  =  2).  Three  patients  received  pallia-
ive  chemotherapy-only  due  to  locally  advanced  disease
nd  contraindications  to  surgery,  two  were  managed  with
xclusive  isolated  limb  perfusion  and  one  was  managed
ith  best  supportive  care.  After  surgery,  ﬁnal  results  were
esection  R0  for  23  patients  and  R1  for  17.  The  median
uration  of  hospital  stay  after  surgery  of  the  local  relapse
as  10.5  days  (range  2—45  days),  and  there  was  no  30-
ay  mortality.  The  median  follow-up  after  treatment  for
ecurrence  was  42.8  months  [95%CI:  24.6—61].  Twenty-eight
atients  were  still  alive  (60.9%)  and  18  have  died,  16  deaths
eing  related  to  the  disease  (34.8%).  New  recurrences  have
een  observed  in  24  patients  (52.2%)  and  were  local  in
ine  patients,  located  in  lymph  nodes  in  one  and  metastatic
n  14  patients.
mage analysis
ll  selected  cases  were  reviewed  to  identify  patients  who
ould  be  eligible  for  percutaneous  cryoablation  as  a  cura-
ive  option  according  to  predeﬁned  selection  criteria  based
n  surgical  recommendations  [1], results  of  previous  stud-
es  on  the  topic  [5,8]  and  our  own  experience  on  soft
issue  tumors  cryoablation  including  cases  presenting  STS
4,6,9,11].  Therefore,  selection  criteria  were:  maximal
iameter  size  of  the  tumor  smaller  than  10  cm,  planned
ryoablation  must  cover  the  entire  lesion  volume,  no  possi-
le  problem  for  the  positioning  of  the  cryoprobes,  distance
o  skin  at  least  5  mm,  distance  to  neurovascular  structures
t  least  3  mm,  absence  of  articular  involvement.
Two  radiologists  (N.L.  and  F.C.),  blind  to  pathology
esults,  reviewed  independently  the  CT  or  MR  images  on
icture  archiving  and  on  the  communication  system  work-
tation  in  order  to  determine  the  feasibility  of  cryoablation
ollowing  these  selection  criteria.  After  the  independent
Criteria  for  percutaneous  image-guided  cryoablation  1073
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IFigure 1. Flowchart of study proﬁle.
interpretation  sessions,  the  two  readers  met  and  reviewed
all  cases  for  which  there  was  a  discrepancy.  Subsequently,
the  two  readers  reached  a  consensus  interpretation  and  cal-
culated  the  maximal  volume  of  cryoablation  (Fig.  2).  The
theoretical  cryoablation  volume  was  measured  by  adding
the  volume  of  each  cryoprobe  (22  cm3,  48  ×  30  ×  30  mm  for
one  IceRod  Plus®)  as  proposed  by  the  manufacturer  (Galil
Medical,  Israel)  in  order  to  be  compared  with  the  surgical
volume  of  the  resection.  Distance  into  the  tissue  must  be
the  shortest  along  the  great  axe  of  the  tumor.  No  skin  exten-
sion  from  the  ice  must  be  attended,  although  the  ice  must
cover  the  entire  targeted  lesion  on  the  short  axes.  However,
cryoprobes  may  be  repositioned  along  the  same  axe  in  order
to  cover  the  whole  tumor  in  two  successive  times.
Statistical analysisInterreader  agreement  was  assessed  by  using  simple  k  coef-
ﬁcients  for  binary  measures.  The  k  coefﬁcients  were  inter-
preted  as  follows:  0—0.20,  slight  agreement;  0.21—0.40,  fair
agreement;  0.41—0.60,  moderate  agreement;  0.61—0.80,
c
T
substantial  agreement;  0.81—1.00,  almost  perfect  agree-
ent  [12].  Median  follow-up  time  was  calculated  by  the
nversed  Kaplan—Meier  method  [13],  and  survival  was  cal-
ulated  as  the  time  of  diagnosis  of  the  recurrence  and  the
ate  of  last  event  with  the  Kaplan—Meier  method  (STATA©
oftware,  College  Station,  Texas,  USA).  All  statistical  tests
Fisher,  2)  were  2-sided  and  a  signiﬁcant  difference  was
onsidered  when  P  <  0.05.  Spearman’s  correlation  was  per-
ormed  to  compare  cryoablation  volume  and  volume  of
urgical  resection  on  pathological  results.  CTCAE  4.0  scale
as  used  to  report  complications.
esults
nterreader agreement for patient selection
riteria
here  was  nearly  perfect  agreement  with  all  determined
election  criteria  between  the  both  readers  to  determine
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he  eligibility  of  patients  for  cryoablation  (k  coefﬁcient
anging  from  0.83  to  0.98)  (Table  1).
atients meeting eligibility criteria for
ossible cryoablation
ollowing  our  selection  criteria,  13  patients  (28.3%)  have
een  identiﬁed  as  eligible  for  cryoablation.  All  of  them  were
reated  with  surgery.  Their  characteristics  are  described
n  Tables  2  and  3.  Focus  on  these  patients,  severe
omplications  rate  was  53.8%  (7/13)  after  surgery  with  a
edian  hospitalization  stay  of  10  days  (range:  4-16)  (Table  4)
hile  among  all  patients,  it  was  47.5%  (19/40)  after  surgery
nd  47.8%  (22/46)  across  all  treatments.
Locations  to  the  trunk,  pelvic  girdle  or  shoulder  were  sig-
iﬁcantly  more  present  in  the  cryoablation  group  (P  =  0.002).
n  this  group,  tumors  were  mainly  located  deeply  (P  = 0.002)
ith  a  great  axes  ≤  5  cm  (P  =  0.044).  High  local  tumor  aggres-
iveness  (P  =  0.016)  and  differentiated  myxoid  liposarcoma
r  myxoﬁbrosarcoma  (P  =  0.007)  were  more  frequent  in  the
ligible  group.
For  these  eligible  patients,  mean  number  of  cryoprobes
equired  would  have  been  2  (range:  1—8).  Mean  planned
ryoablation  volume  was  73  cm3 (25—200),  which  was  higher
han  the  mean  ﬁnal  tumoral  volume  after  surgical  resec-
ion  at  37  cm3 (0.12—168)  (P  =  0.0002).  The  correlation
oefﬁcient  between  the  ﬁnal  resected  tumoral  volume  on
Table  1  k  coefﬁcients  for  assessment  of  interreader
agreement  for  binar  imaging  features.
Feature  k
Maximal  diameter  size  of  the  tumor  smaller
than  10  cm
0.91
Planned  cryoablation  must  cover  the  entire
lesion  volume
0.93
No possible  problem  for  establishment  of
cryoprobes
0.87
Distance  to  skin  at  least  5  mm  0.83
Distance  to  neurovascular  structures  at  least
3  mm
0.86
Absence  of  articular  involvement  0.98
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Table  2  Patient  characteristics  between  selected  and  non-se
Selected  population  for  cryoab
(group  1)
Number  of  patients 13  
Gender
Male  9  (69.2%)  
Female  4  (30.8%)
Age  (years)  63.4  
Mean  (range)  (23.4—80.7)  
Associated  morbidity
Yes  10  (76.9%)  
No  3  (23.1%)  
ASA  =  3  3  (23.1%)  N.  Lippa  et  al.
athological  analysis  and  the  planned  cryoablation  for  each
elected  tumor  was  adequate  (0.774).
iscussion
s  patients  presenting  STS  often  experience  multiple  local
ecurrences  [14],  in  particular  after  inadequate  initial  treat-
ent,  cryoablation  could  be  an  interesting  alternative
ption  [3,4,8,15]. One  of  the  major  advantages  of  cryoab-
ation  compared  with  other  ablation  techniques  is  that  the
blation  area  can  be  monitored  intraprocedurally.  Moreover,
he  iceball  encompassing  the  tumor  with  safety  margins  is
redictive  for  a  successful  procedure  [10,16].  However,  only
 small  number  of  cryoablation  procedures  on  sarcomas  have
een  reported  until  now  [9,17,18].  It  can  be  explained  by
he  fact  that  this  treatment  is  rarely  discussed  in  multi-
isciplinary  team  meeting  and  only  proposed  case-by-case
s  last  therapeutic  option,  with  palliative  objectives  and
or  patients  with  poor  prognosis.  Moreover,  as  data  about
he  role  of  cryoablation  in  soft-tissue  tumors  are  currently
carce,  indication  of  this  treatment  is  limited.  Our  study
ried  to  propose  a  standardization  of  selection  of  patients.
ur  criteria,  although  arbitrary,  have  identiﬁed  an  eligible
roup  of  patients  with  local  relapse  of  STS  and  may  be  help-
ul  to  enlarge  the  indication  of  such  approach.
One  advantage  of  cryoablation  is  to  limit  morbidity  due
o  the  preservation  of  collagens  structures  [19]. As  opposed
o  the  kidney  tumors,  where  good  candidates  for  cryoab-
ation  are  also  good  candidates  for  partial  nephrectomy,
he  functional  and  esthetic  prognosis  may  be  taken  into
ccount  for  soft  tissue  tumors.  Moreover,  it  is  likely  that
mall  tumors  may  beneﬁt  from  a  non-invasive  approach.
lthough  the  patients  have  an  adequate  local  control  after
urgery,  complications  were  observed  in  47.5%  of  cases  in
ur  study.  Therefore,  cryoablation  may  probably  be  pro-
osed  for  poor  surgical  candidates,  or  to  limit  postoperative
orbidity.
In  case  of  oligometastatic  patients  with  local  recurrence
ligible  for  cryoablation  (four  patients  in  our  study),  these
atients  may  be  also  eligible  for  an  overall  minimal  inva-
ive  strategy,  combining  ablation  techniques  in  both  sites  of
ecurrence  and  metastases  [16].  This  could  be  achieved  in
he  same  time  or  not.
lected  patients  for  cryoablation.
lation Non-selected  population  for
cryoablation
(group  2)
33
21  (63.6%)
12  (36.4%)
65.2
(29.4—84.2)
24  (72.7%)
9  (27.3%)
7  (21.2%)
Criteria  for  percutaneous  image-guided  cryoablation  1075
Table  3  Tumor  characteristics  (per  patient)  between  selected  and  non-selected  patients  for  cryoablation.
Selected  population  for  cryoablation
(n  =  13)
(group  1)
Non Selected  population  for  cryoablation
(n  =  33)
(group  2)
Pathology
Unclassiﬁed/Myxoﬁbro
(MFS)/Myxoﬁbroblastic
sarcomas
4 (30.8%)  20  (60.6%)
Liposarcomas  (LPS)  6  (46.1%)  9  (27.3%)
Other  3  (23.1%)  4  (12.1%)
Co-existing  metastatic
disease
4 (30.8%)  23  (69.7%)
Location
Trunk  3  (23.1%)  4  (12.1%)
Shoulders  3  (23.1%)  2  (6.1%)
Upper  extremities  —  7  (21.2%)
Pelvic  girdle  3  (23.1%)  —
Lower  extremities  4  (30.8%)  20  (60.6%)
Localization
Superﬁcial  3  (23.1%)  8  (24.2%)
Profound  9  (69.2%)  6  (18.2%)
Both  1  (7.7%)  19  (57.6%)
Multiple  local  recurrences  1  (7.7%)  6  (18.2%)
Size
Mean  size  (mm)  48  (10—87)  71  (12—178)
≤50  mm  8  (61.5%)  9  (27.3%)
s
f
s
s
s>  50  mm  5  (38.5%)  
Interestingly,  in  our  population  selected  for  cryoablation,
recurrences  were  mainly  located  in  the  shoulders,  pelvic  gir-
dle  or  trunk.  This  is  probably  due  to  the  early  detection  of
small  recurrences  with  MRI  that  is  more  often  performed  in
these  sites  and  rarely  performed  elsewhere.  If  explorations
with  MRI  or  PET-CT  [20—22]  were  more  widely  available,
eligible  population  for  cryoablation  would  be  wider.
A  main  limitation  of  cryoablation,  as  for  other  tech-
niques,  seems  to  be  observed  if  tumors  are  too  close  to  the
t
r
H
b
Table  4  Complications  (per  patient)  and  subgroup  analysis  bet
Complications
n  (rate  %)
Population  with  STS
recurrence
(n  =  46)
All  therapeutic  options
(n  =  46)
None  3  (6.5%)  
Minor  4  (8.7%)  
Mild  17  (37.0%)  
Severe  22  (47.8%)  
After  surgery  combined
or  not
(n =  40)
None  3  (7.5%)  
Minor  3  (7.5%)  
Mild  15  (37.5%)  
Severe  19  (47.5%)  24  (72.7%)
kin.  Although  cryoablation  could  be  technically  performed
or  all  tumors  with  a  curative  objective,  i.e.  with  adequate
ecurity  margins  (5  mm)  as  reported  in  the  literature  [3],  our
election  criteria  were  deﬁned  to  avoid  morbidity,  including
kin  necrosis.  It  explains  why  we  excluded  tumors  closer  to
he  skin  and  neurovascular  structures  than  5  mm  and  3  mm,
espectively,  although  surgery  has  been  technically  possible.
owever  in  order  to  enlarge  the  population  of  patients  eligi-
le  for  cryoablation,  this  distance  of  5  mm  may  be  discussed
ween  selected  and  non-selected  patients  for  cryoablation.
Selected  population
for  cryoablation
(n =  13)
(group  1)
Non-selected  population
for  cryoablation
(n =  33)
(group  2)
—  3 (9.1%)
2  (15.4%)  2 (6.1%)
4  (30.8%)  13  (39.4%)
7  (53.8%)  15  (45.4%)
—  3 (11.1%)
2  (15.4%)  1 (3.7%)
4  (30.8%)  11  (40.7%)
7  (53.8%)  12  (44.4%)
1076  N.  Lippa  et  al.
Figure 2. A. This T2-weighted MR image without fat saturation showed a 52 mm-recurrence of pleomorphic sarcoma in the posterior loge
of the right calf. Dashed arrows showed the neuro-vascular structures, which must be avoid by the cryoablation. The adequate number of
probes was determined in order to cover the whole tumor by inserting six cryoprobes (two on the top, two in the middle and two in the lowest
part) along the great axe of the tumor (arrows) and minimizing the distance. B. This post contrast T1-weighted MR image with fat saturation
showed a recurrence of unclassiﬁed sarcoma of the left leg (arrow). Although neuro-vascular structures were located deeply (dashed arrow),
the subcutaneous extension prevents to perform the cryoablation safely. C. This T2-weighted MR image without fat saturation showed a
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c0 mm recurrence of myxoid liposarcoma in the pelvic ﬂoor. The ac
f ice to surrounding tissue. No other limitation was observed. Th
een performed with only one cryoprobe under CT guidance and ge
f  cryoablation  can  be  associated  with  CO2 dissection  [23,24]
r  with  a  surgical  reconstruction,  as  often  performed  with
urgery.
Our  study  has  limitations.  Its  retrospective  nature  and  the
mall  number  of  patients,  limit  the  conclusions  of  this  study.
ur  small  selected  population,  with  its  intrinsic  character-
stics,  creates  also  a  bias  in  the  interpretation  of  results.
election  criteria  for  cryoablation  were  mainly  arbitrary
erived  from  surgical  criteria  in  order  to  be  compared  with
revious  studies  on  STS.  However  these  criteria  may  dif-
er  from  those  of  cryoablation.  Then,  they  were  adapted
ccording  to  results  of  previous  studies  on  the  topic  and
ur  own  experience  on  soft  tissue  tumors  cryoablation.  Con-
erning  inter-reader  agreement,  even  good  agreement  on
he  size  of  the  tumor  or  number  of  cryoprobes  has  been
btained;  the  geometry  of  needle  placement  as  well  the
umber  of  probes  may  be  still  subject  to  debate  as  often
ncounter  in  clinical  practice.  It  is  rarely  recommended
o  use  a  single  cryoprobe  (except  for  very  small  lesions),
ecause  the  increase  in  temperature  with  distance.  Combin-
ng  two  needles  increases  the  size  of  the  ice  ball,  ensuring
ore  satisfactory  safety  margins.  A  repositioning  of  the
robes  may  be  used  to  limit  their  number  [7]  but  it  is  still
ebated  in  case  of  STS  in  order  to  avoid  re-implantation.
A
T
toute (arrow) was determined in order to minimizing the extension
ly one cryoprobe was planned to be use. D. The cryoablation has
l anesthesia (arrow).
inally,  no  patients  in  this  study  were  treated  with  cryoab-
ation  in  order  to  test  our  hypothesis.
In  summary,  despite  the  usual  limitations  of  retrospective
tudies,  and  although  our  study  does  not  provide  outcomes
ata  for  patients  selected  and  treated  with  these  eligibility
riteria,  our  selection  criteria  may  improve  the  standard-
zation  of  selection  of  patients  who  could  be  candidates  for
ryoablation.  They  may  enlarge  the  indication  of  percuta-
eous  image-guided  cryoablation,  which  could  be  proposed
s  an  alternative  to  surgery  in  case  of  poor  surgical  candi-
ates.  Prospective  feasibility  studies  applying  the  selection
riteria  developed  are  now  required  to  determine  outcomes.
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